Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
(4) - EconoTimes)
KING OF PRUSSIA, Pa., May 31, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 22, 2017 and May 30, 2017, the grant of inducement stock options to purchase an aggregate of 100,000 shares of the Company’s common stock to two new employees. These awards were granted pursuant to the Trevena, Inc. Inducement Plan as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).
The first stock option, for 47,500 shares, has an exercise price per share of $2.98, the closing stock price on May 22, 2017; the second stock option, for 52,500 shares, has an exercise price per share of $2.40, the closing stock price on May 30, 2017. Each option has a ten-year term and will vest with respect to one-fourth of the total number of shares subject to the option on each of first, second, third, and fourth anniversaries of the grant date.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734 for pain. The Company maintains an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
